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Abstract
Brazilian Vaccinia virus had been isolated from sentinel mice, rodents and recently from humans, cows and calves during
outbreaks on dairy farms in several rural areas in Brazil, leading to high economic and social impact. Some phylogenetic
studies have demonstrated the existence of two different populations of Brazilian Vaccinia virus strains circulating in nature,
but little is known about their biological characteristics. Therefore, our goal was to study the virulence pattern of seven
Brazilian Vaccinia virus strains. Infected BALB/c mice were monitored for morbidity, mortality and viral replication in organs
as trachea, lungs, heart, kidneys, liver, brain and spleen. Based on the virulence potential, the Brazilian Vaccinia virus strains
were grouped into two groups. One group contained GP1V, VBH, SAV and BAV which caused disease and death in infected
mice and the second one included ARAV, GP2V and PSTV which did not cause any clinical signals or death in infected BALB/
c mice. The subdivision of Brazilian Vaccinia virus strains into two groups is in agreement with previous genetic studies.
Those data reinforce the existence of different populations circulating in Brazil regarding the genetic and virulence
characteristics.
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Introduction
Vaccinia virus (VACV) is the prototype virus of the family
Poxviridae and it was used as a live vaccine during the smallpox
vaccination campaign. The World Health Organization declared
smallpox, the contagious and deadly disease caused by Variola virus,
eradicated in 1980 [1]. In spite of that, the poxviruses still have a
great impact in human and animal health due to the existence of
emerging and reemerging zoonotic agents in this family. Cases of
Cowpox virus human infections have been reported in Europe [2,3].
Monkeypox virus is endemic in the tropical rainforest villages of
Central and Western Africa, causing sporadic cases in humans.
Moreover, 37 confirmed human cases have been recently reported
in the United States [4,5].Outbreaks of Buffalopox virus affecting
buffaloes, cows and humans have been reported in countries as
India, Egypt and Bangladesh [6,7].
In Brazil, several strains of VACV have been isolated since the
60’s. Some of these strains were isolated from sentinel mice, such
as Cotia [8,9] and SPAn232 (SAV) [10]. BeAn58058 (BAV) was
isolated from a rodent of Oryzomis genus [11] while Belo Horizonte
(VBH) was isolated from an outbreak affecting laboratory mice
[12]. Since the 90’s, bovine vaccinia outbreaks have been reported
occurring in many rural regions in Brazil. All the VACV isolates,
such as Cantagalo virus, Arac ¸atuba virus, Guarani P1 virus,
Guarani P2 virus, Passatempo virus, were equally pathogenic to
cattle regarding the macroscopic evolution pattern of lesions.
Initial acute lesions were associated with the appearance of
erythema evolving to vesicles, papules and pustules, ending with
the formation of scabs. Those lesions were mainly observed on the
teats of cows and on the nose and mouth of calves [13–18]. In all
those bovine outbreaks, human infections were also reported. In
humans, hands and face were the mainly affected regions and the
lesions were similar to those observed in cows and calves.
Lymphadenopathy was also frequently observed in humans
[14,16]. The vaccinia outbreaks cause economic loss mainly due
to decrease in milk production and to the fact that milkers often
stand back from working [13,16,19].
Due to the importance of VACV in human and animal
medicine, some studies have been conducted in order to
characterize those Brazilian vaccinia strains (BR-VACV). It was
demonstrated that there is genetic variability among them which
could reflect on different biologic characteristics; however there is
little information about the virulence patterns of BR-VACV. Leite
and collaborators (2007) demonstrated based on the structure of
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of BR-VACV. Phylogenetic analyses based on sequences of genes
A56R, B19R, E3L [18] and of ten genes related with virulence
and host-range [20] demonstrated the existence of two well
defined groups of BR-VACV [18,20].
The origin of VACV is unknown [2] and the most appropriate
animal model for studying VACV virulence is still uncertain.
Different animal models have been used to study poxvirus
virulence and the murine model is considered a good animal
model due to the availability of well-defined inbred strains [21].
Vaccinia virus infection has been studied after different infection
routes, such as intravenous, intraperitonial, intradermal, intracra-
nial, and intranasal [22–28]. The intranasal route is the natural
way of infection by Variola virus and it is considered the most
frequent route of Orthopoxvirus transmission [29]. Moreover, it had
already been described that intranasal and intracranial inoculation
of moderate doses of VACV strain Western Reserve (WR) can
cause systemic infections that permit the observation of differences
in virulence patterns among different strains of VACV
[23,27,30,31]. Thus, due to the existence of genetic diverse
populations of VACV in Brazil and to the lack of studies focused
on their biologic characteristics, the aim of the present work was to
study the virulence and tropism patterns of different BR-VACV,
after intranasal infection of BALB/c mice.
Materials and Methods
Viruses and cells
Brazilian Vaccinia virus strains used in this study are shown in
Table 1. The Vaccinia virus, strain Western Reserve (VACV-WR),
kindly provided by Dr. C. Jungwirth (Universita ¨t Wu ¨rzburg,
Germany), was used as a highly virulent reference strain in murine
model by intranasal infection [23,32]. Lister Butantan strain (LST-
BUT), kindly provided by Instituto Butantan (Sa ˜o Paulo, Brazil) is
a vaccine strain and it was used as a low virulence reference strain
[27,32]. All virus stocks were grown in Vero cells (ATCC CCL-81)
cultivated in Eagle’s minimum essential medium (MEM) supple-
mented with 5% of fetal calf serum (Cultilab, Brazil) and
antibiotics, at 37uCi n5 %C O 2 atmosphere. Viruses were purified
on sucrose gradients as described elsewhere [33].
Animal experimentation
For all animal experimentation, four-weeks-old male BALB/c
mice were used. Mice were housed in filter-top micro isolator
cages and provided with commercial mouse feed and water ad
libitum. All the animal experimentation was carried out in
accordance with regulations and guidelines of Committee of
Ethics for Animal Experimentation from Universidade Federal de
Minas Gerais/Brazil.
BALB/c mice were anesthetized by intraperitonial injection of
ketamine and xilazine (3.2 mg and 0.16 mg/mice, in phosphate
buffered saline (PBS) 0.9%, respectively) and inoculated by
intranasal route. Mice belong to negative control group were
inoculated with 10 ml of PBS [32].
Survival rate and lethal dose (LD50) in mice
For the survival rate analysis, mice were infected with 10
6 PFU
(plaque forming units) of BR-VACV BeAn58058 (BAV), SpAn232
virus (SAV), Belo Horizonte virus (SAV), Arac ¸atuba virus (SAV), Guarani
P1virus(GP1V), Guarani P2virus(GP2V), Passatempovirus (PSTV)and
with the control strains VACV-WR and LST-BUT. To establish
the lethal dose of 50%of the animals (LD50) mice wereinfected with
virus titers ranging from 10
3 to 10
8 PFU of BAV, SAV, VBH,
GP1V and control strain in a total volume of 10 ml which was
dropped by intranasal route. For both experiments, mice were daily
observed during 20 days post inoculation (d.p.i.) or until their death.
Mice that survived until day 20 p.i. were euthanized.
Vaccinia virus tropism in mice
Groups of four, BALB/c mice were infected with 10
6 PFU of
each purified virus strain in a total volume of 10 ml which was
dropped by intranasal route. Mice were daily weighted and those
ones that had lost more than 25% of their initial body weight were
euthanized with an overdose of anesthetics (ketamine+xilazine).
Those animals had their organs (trachea, lungs, heart, kidneys,
liver, brain and spleen) asseptically removed after euthanasia.
Those mice that survived were euthanized on day 12 p.i. and their
organs and blood were also collected.
In order to compare the replication of all VACV strains in lungs,
(a main site of viral replication in this model), a virus multiplication
kinetic was made at days 1, 3 and 5 post intranasal infection with
10
6 PFU of BAV, SAV, VBH, GP1V, ARAV GP2V, PSTV, and
with the control strains VACV-WR and LST-BUT.
Virus titration
The organs were macerated in MEM (Gibco, USA) and
centrifuged at 20006g for 3 min, 4uC. Supernatant fluids from
macerated organs were collected and virus titer (PFU/g) was
determined by plaque forming assay in Vero cell culture [34].
Neutralization test
Blood samples were collected from BALB/c mice just before
euthanasia. The serum was heated at 56uC for 30 min and used in
Table 1. Brazilian Vaccinia virus strains used in this study.
Strain, isolate (abbreviation) Source Isolation Year Geografic isolation (State) Reference
BAV Rodent, Oryzomis sp. 1963 Para Da Fonseca et al., 1998
SAV Rodent, sentinel 1965 Sa ˜o Paulo Da Fonseca et al., 2002
VBH Rodent, Balb-c mice 1993 Minas Gerais Trindade et al., 2004
ARAV Bos taurus 2000 Sa ˜o Paulo Trindade et al., 2003
GP1V Bos taurus 2001 Minas Gerais Trindade et al., 2006
GP2V Bos taurus 2001 Minas Gerais Trindade et al., 2006
PSTV Bos taurus 2003 Minas Gerais Leite et al., 2005
*BAV, BeAn58058; SAV, SpAn232 virus; VBH, Belo Horizonte virus; ARAV, Arac ¸atuba virus; GP1V Guarani P1 virus; GP2V: Guarani P2 virus; VACV-WR, Vaccinia virus Western
Reserve.
doi:10.1371/journal.pone.0003043.t001
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neutralization titer was expressed as the reciprocal of the highest
dilution that exhibited 50% of plaque formation inhibition, when
compared to cells infected with VACV WR (positive control).
Histopathologic analysis
Fragments of lungs were fixed in 10% neutral-buffered formalin
and routinely processed for paraffin embedding. Sections (5 mm)
were cut on a standard rotary microtome and placed on glass slides
for staining with hematoxylin and eosin (H&E). Other unstained
sections were used for immunohistochemical analysis to localize
viral antigen. Histological sections were examined by an
experienced pathologist and classified in mild, moderate or severe
according to lesion extent and severity.
Immunohistochemistry
For immunohistochemistry analysis, deparaffinized lung sec-
tions were washed in PBS for 15 min at room temperature.
Antigen retrieval was performed by incubating the slides in a
specific solution (Target Retrieval Solution, S1700, Dako Corpo-
ration, USA) at 98uC for 20 min. Endogenous peroxidase activity
was abolished by incubation with 3.5% H2O2 for 30 min, which
was followed by incubation with 1:20 normal goat serum (NGS)
and 2% bovine serum albumin (BSA) for 30 min each at room
temperature in humid chamber. Primary rabbit anti-H3L protein
from VACV [35] was used at the dilution 1:10.000, and the
antibody incubation was performed overnight at 4uC in humid
chamber. Secondary biotinylated antibody was goat anti-rabbit,
followed by streptavidin-peroxidase complexes (LSAB2 system –
HRP, DAKO, USA). The reaction was visualized by incubating
the section with 3,3-diaminobenzidine tetrahydrochloride (Sigma,
St. Louis, MO) and counter staining with hematoxylin. Tissues
from non-infected animals were used as negative controls.
Technical control was performed by the omission of the primary
antibody. The sections were examined by Olympus BX51
microscope and digital images were acquired for documentation.
Polymerase chain reaction (PCR)
For viral DNA detection, a semi-nested PCR for vaccinia growth
factor (vgf) gene amplification was used (unpublished data). In the first
reaction, 2 mlofclarifiedtissuesampleswereusedastemplatewithout
previous DNA extraction, added to 18 ml of the PCR reaction
mixture. PCR products from the second round of amplification were
fractionated by electrophoresis on 8% PAGE and silver stained.
Statistical analysis
Significance variations were calculated using the Student’s t-test
(p#0.05: statistical significance). Analysis of significant differences
on weight curves and survival were done, respectively, by Wilcoxon
paired test (p#0.05: statistical significance) and the log-rank test
(p#0.05: statistical significance). Data were analyzed for individual
mice. Statistical analysis was performed using GraphPad Prism
Software, version 3.0. (GraphPad Software, Inc., San Diego, CA).
Results
Clinical signs
Seven BALB/c mice were infected with 10
6 PFU of each VACV
strain by intranasal route. The induction of clinical signals such as
ruffling fur and arching back was observed in all animals inoculated
with VBH (Figure 1A), BAV, SAV, GP1V and the control VACV-
WR within days 2–3 p.i. Five mice inoculated with BAV and SAV
strains presented periocular alopecy and closed eyes with inflam-
mation on day four p.i. (Figure 1B). Mice inoculated with GP1V
presentedpeniswithbalanopostitison daythree p.i.(Figure 1C),but
those animals recovered from it after a few days.
The clinical signals of mice infected with BAV, SAV, GP1V,
VBH and the control strain WR were associated with severe
weight loss up to 25% on day five (WR), four (BAV and SAV) or
three p.i. (VBH and GP1V) (Figure 2A). On the other hand, no
clinical signals were observed in mice infected with PSTV, ARAV,
GP2V or with the other control strain LST-BUT, as well as the
control mice, inoculated with PBS. None of those animals died or
lost weight (Figure 2B) during the twelve days of observation.
Survival rate and lethal dose (LD50)
To establish the survival rate, seven BALB/c mice were infected
with 10
6 PFU of each VACV strain by intranasal route and
observed for 20 days. All mice infected with WR died on sixth day
p.i., 50% of mice infected with GP1V died on fourth day p.i. and
80% of mice infected with VBH and SAV died on days eighth and
ninth p.i., respectively (Figure 3).
Since strains BAV, SAV, GP1V, VBH and WR were the only
ones able to induce clinical signals and/or death of mice infected
with 10
6 PFU, we performed an assay to estimate the lethal dose of
those VACV strains. For that, mice were infected by intranasal
route with virus doses ranging from 10
3 to 10
8 PFU of BAV, SAV,
GP1V, VBH and WR. According to the LD50 estimation, VBH
was the most virulent strain (LD50=10
3 PFU), followed by WR
(LD50=10
4 PFU), SAV and GP1V (LD50=10
6) and BAV
(LD50=5 610
7 PFU) (Table 2).
Figure 1. Clinical signs of BALB/c BR-VACV infected mice. Seven
BALB/c mice were intranasally infected with 10
6 PFU/10 mla n d
observed daily. 1A) Ruffling fur and arching back in mice infected with
VBH on day 3 p.i. 1B) Periocular alopecy caused by BAV on day 4 p.i. 1C)
Penis with balanopostitis on day 3 p.i. of mice infected with GP1V. 2A,
2B, 2C). No clinical signals were observed in control mice inoculated
with PBS.
doi:10.1371/journal.pone.0003043.g001
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Neutralizingantibodies withtiters rangingfrom 1:40to 1:60 were
detected in mice infected with LST-BUT, ARAV, GP2V and
PSTV. Since mice infected with 10
6 PFU of WR, BAV, SAV,
GP1V and VBH strains died or were euthanized shortly after
infectionbecausetheyhadlostmorethan25%ofinitialweightbody
it was not possible to perform neutralization assays with clinical
samples from those mice. Moreover, neutralizing antibodies could
not be detected in sera in initial days post infection of mice infected
with WR, BAV, SAV, GP1V and VBH. Neutralizing antibodies
were also not detected in mice inoculated with PBS.
VACV replication in different organs
Infectious virus particles were detected in trachea, liver, spleen,
lungs, heart, brain and kidneys from mice infected with BAV, SAV,
GP1V, VBH and the control VACV-WR on the day that animals
presented 25% of weight loss (Figure 4). The highest titers of virus
were observed in trachea, ranging from 10
8 PFU/g of organ (mice
infected with VBH) to 10
9 PFU/g (mice infected with WR, SAV,
GP1V and BAV). In the lungs, viral titers ranged from 10
8 PFU/g
(mice infected with WR, BAV, GP1V and VBH) to 10
9 PFU/g
(mice infected with SAV) The only organ in which no virions were
detected by the method of plaque forming units was the spleen of
mice infected with VACV WR, but virus was detected by PCR in
that organ.Inall organsofmice infected with ARAV,GP2V,PSTV
and control LST-BUT no viral infectious particles were detected.
Virus replication kinetic in the lungs
The replication kinetics of VACV strains in the lungs was done
on days 1, 3 and 5 post intranasal inoculations of 10
6 PFU of BAV,
SAV, GP1V, VBH, ARAV, GP2V, PSTV and control strains WR
and LST-BUT. In mice infected with WR and BAV, infectious
particles were detected the lungs from day 1 to day 5 p.i. Infectious
particles of VBH, GPV1V and SAV were detected in the lungs
from the day 3 until day 5 p.i. (Figure 5). No infectious viral
particles were detected in any of the analyzed days in the lungs of
mice infected with ARAV, GP2V, PSTV or LST-BUT.
Histopathological and Immunohistochemistry
The histopathological analyses of lungs were performed and
mice infected with all VACV strains had some degree of
Figure 3. Survival curve of mice infected with BR-VACV. Groups of seven mice were inoculated by the intranasal route with 10
6 PFU of BR-
VACV BAV, GP2V, control LST-BUT, ARAV, PSTV, SAV, VBH, GP1V and control WR. The control group was inoculated with PBS. Mice were monitored
daily until day 20 p.i.
doi:10.1371/journal.pone.0003043.g003
Table 2. Lethal dose of 50% of mice infected by intranasal
route.
VACV strains LD50 (PFU)*
VBH 10
3
WR 10
4
GP1V 10
6
SAV 10
6
BAV 5610
7
*Groups of mice (n=7) were followed for 20 days pi or until their death with
doses ranging from 10
3 until 10
8 PFU/ml.
doi:10.1371/journal.pone.0003043.t002
Figure 2. Body weight of BALB/c mice infected with BR-VACV.
Groups of mice (n=4) were inoculated with 10
6 PFU of VACV by the
intranasal route: (A) WR, BAV, SAV, VBH GP1V, and (B) LST-BUT, ARAV,
GP2V and PSTV. The weight of the mice was determined daily and those
that lost more than 25% of their initial weight were euthanized. The
percentages of median weight relative to their initial weight were
plotted. The weight of uninfected mice (control) was followed as well
(A, B). The error bars indicate the standard deviations. Significance
variations were calculated using the Student’s t-test (P#0,05: statistical
significance).
doi:10.1371/journal.pone.0003043.g002
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of mice infected with BAV, GP1V, SAV, VBH and the control
VACV-WR (Figure 6). In mice infected with ARAV, PSTV,
GP2V and the control strain LST-BUT, mild to moderate lesions
were observed in the lungs (Figure 7). All mice developed
interstitial pneumonia and bronchiolitis. Lesions in lungs were
degenerative, necrotizing, hemorrhagic, and contained predomi-
nantly lymphocytic and histiocytic interstitial infiltrates. Hyper-
plasia of bronchial epithelial cells, fibroblasts, and pneumocytes
were also observed. Although all animals had lung lesions, there
Figure 4. Viral titers in organs of mice infected with BR-VACV. Mice were infected by the intranasal route with 10
6 PFU/10 ml with BR-VACV
strains: VBH, BAV, SAV, GP1V and VACV-WR. Organs were collected and titrated on the day that 25% weight loss occurred and the mice were
euthanized. The results presented were obtained by the average titers from three mice. Titers were calculated as PFU/g tissue.
doi:10.1371/journal.pone.0003043.g004
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patterns of lesions. Pulmonary lesions were diffuse, severe to
moderate on days 1, 3 and 5 p.i. in mice infected with BAV,
GP1V, VBH, SAV and control strain WR (Figure 6). Interalveolar
septa thickening and alveolar collapse due to mild or moderate
mononuclear inflammatory cell infiltrate were observed mainly in
mice infected with WR and BAV. Alveolar wall rupture and
bronchioles destruction with cystic spaces formation were observed
in mice infected with GP1V, SAV and VBH. Mucosal epithelial
necrosis was also observed in mice infected with VBH and WR.
On the other hand, pulmonary lesions were focal and mostly mild
in mice infected with ARAV, GP2V, PSTV and the control strain
LST-BUT (Figure 7). Hemorrhagic areas were frequently noticed.
No lesions were observed in lungs of mice inoculated with PBS.
Immunohistochemistry showed anti-H3L positivity in lungs.
Positive H3L expression was evident in cytoplasm of inflammatory
cells of lungs from mice infected with all strains (Figure 6, 7).
Strong immunopositivity against H3L was present in areas of
intense inflammatory infiltrate.
Discussion
Brazilian VACV strains showed different virulence profiles after
intranasal infection of BALB/c mice. Based on their biologic
characteristics the studied VACV strains could be divided into two
main groups corroborating the genetic data from previous studies
[20,36]. The first one grouped the high virulent strains SAV,
VBH, BAV, GP1V and the control VACV-WR. The second
group was represented by the low virulent strains ARAV, GP2V,
PSTV and the vaccine strain LST-BUT. Previous studies had
demonstrated that VACV WR is a high virulent strain and since
LST-BUT is a vaccine strain
1, it was expected that it present a low
virulent pattern [27].
The VACV strains SAV, VBH, GP1V, BAV and VACV-WR
caused severe morbidity, with clinical signals such as ruffled fur,
arching back and weight loss in infected mice (Figure 2). Those
strainsshowedthe highestviraltiters inthe initial sitesof infectionas
trachea and lungs, but also presented a broad tropism in BALB/c
mice, spreading to other organs, including brain, liver, kidneys,
heart and spleen. Similar results were observed by Abdalrhman and
collaborators (2006), when mice infected with 5610
5 PFU of
VACV-WR by intranasal route had a weight loss at the third day
p.i. reaching 25% of weight lost at the fifth day p.i. The highest viral
titers were observed in the lungs, but virions were also detected in
liver, kidneys, heart and brain. The VBH strain presented the
highest LD50 (10
3 PFU) and was the strain that induced 25% of
body weight loss sooner than other strains, showing the highest
virulence pattern among all the studied strains (Table 2).
The observation of clinical signs in addition to the presence of
virions in different organs gives support to the idea that SAV,
VBH, GP1V, BAV and control VACV-WR strains are able to
cause systemic disease after intranasal infection. Lung tissues
affected by pneumonia were stained by anti-H3L antibody
confirming the presence of SAV, VBH, GP1V, BAV and the
control VACV-WR in the lungs of mice after intranasal infection.
These findings are in accordance with studies showing pneumonia,
characterized by severe alveolar edema, acute necrotizing
bronchiolitis and peribronchiolitis as well as neutrophilic infiltrate
in the intersticium of lungs from mice infected with VACV WR
[29,37]. Differences regarding the mortality were observed in this
group; except for BAV, all other strains caused death of infected
animals after infection with 10
6 PFU by intranasal route. It is
interesting to note that BAV was isolated from a naturally infected
rodent and one could propose that its morbidity pattern could be a
consequence of the adaptation of BAV to rodents [11], but more
studies involving these strains are necessary to elucidate that.
The second group was represented by ARAV, GP2V, PSTV
and the control strain LST-BUT that did not cause clinical signs,
weight loss or death of infected mice. Previous studies already
showed that infection of in BALB/c mice inoculated with 5610
5
PFU of Lister (Elstree) also did not induce weight loss in those
animals. In contrast as in this work where infectious particles were
detected in lungs of mice inoculated with LST-BUT or ARAV,
GP2V and PSTV those studies [23,27,32] demonstrated the
presence of infectious viral particles in the lungs of mice infected
with Lister (Elstree) by plaque assay in Vero cells, as we did.
Although the strain LST-BUT is derived from Lister (Elstree),
there is no apparent documentation of plaque purification before
the distribution of the Lister strain around the world [38], and it
could be that different virus populations were favored or evolved
in response to different growing conditions in many laboratories.
In fact genetic differences have already been demonstrated among
Lister and Lister derived strains [38], including LST-BUT [20].
On the other hand, infectious viral particles of Lister Elstree could
not be detected in liver, kidneys, heart and brain of infected mice
[23,27,32], as was observed in this work, since no infectious
particles were detected in organs as trachea, lungs, brain, liver,
kidneys, heart and spleen by plaque assay in Vero cells when mice
were inoculated with LST-BUT or ARAV, GP2V and PSTV.
Despite focal and mild lesions observed in lungs of mice infected
with ARAV, GP2V, PSTV and the control strain LST-BUT, no
infectious particles were detected in those organs by plaque assay
in Vero cells. As mentioned, low replication rates of those strains
and the little sensitivity of plaque assay could explain this fact,
since histological alterations and immunopositivity against the
virus confirmed its presence in the lungs. The absence of clinical
signals, the presence of lesions in lungs associated with the
presence of virus in that organ and the detection of neutralizing
antibodies point to the development of a sub-clinical infection in
mice after inoculation of GP2V, ARAV, PSTV and the control
strain LST-BUT by intranasal route.
This grouping of Brazilian VACV strains based on biological
characteristics is in agreement with previous phylogenetic studies
based on the analysis of genes related with tropism and virulence.
Some studies showed that strains BAV, SAV, VBH and GP1V are
Figure 5. Kinetics of BR-VACV replication in the lungs of
infected mice. Mice were inoculated by the intranasal route with 10
6
PFU/10 ml of VBH, BAV, SAV, GP1V and VACV-WR. Viral titers were
estimated in lungs on days 1, 3 and 5 p.i. Titers are expressed as PFU/g
tissue. The results presented were obtained by the average titer in
organs from three mice. The error bars indicate the standard deviations.
doi:10.1371/journal.pone.0003043.g005
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hand, strains PSTV, ARAV and GP2V are closely related to each
other. [20,36] Drumond and collaborators (2008) showed that
BAV, SAV, VBH, GP1V, ARAV, GP2V and PSTV are not close
to from LST-BUT, one vaccine strain used during Smallpox
Eradication Campaign, in Brazil. In this work we showed that in
addition to the genetic differences, BAV, SAV, VBH and GP1V
are also biologically different from LST-BUT, in Balb/c mice after
Figure 6. Histological and immunohistochemical analysis of lungs from WR, BAV, GP1V, SAV and VBH VACV infected mice.
Histological sections of lungs from mice infected with 10
6 PFU of VACV were performed on days 1, 3 and 5 p.i. and positive anti-H3L expression was
evident in inflammatory cell cytoplasms (inserts, arrow-heads) on day 3 p.i in mice infected with WR, BAV, GP1V, SAV and VBH. Intensity of lesions
varied from severe to moderate during the five-day study period. Interstitial pneumonitis was observed in mice infected with all virus strains.
Thickening of the interalveolar septa (thin arrows) was observed mainly in mice infected with VACV-WR and BAV, and characterized by mild or
moderate mononuclear inflammatory cell infiltrate. Alveolar enlargement (white arrows) due to diffuse alveolar wall rupture and cystic structures
lined by bronchial-type epithelium (black arrows) were observed in lungs of mice infected with GP1V, SAV and VBH. Extensive necrosis of bronchial
mucosa (black arrow-head) in mice infected with VBH was observed at the fifth day p.i. No lesions or specific immunostaining (white arrow-heads)
were detected in the lungs of non-infected mice. Original magnifications: 635 and 6350 (inserts).
doi:10.1371/journal.pone.0003043.g006
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presented similar biological characteristics to LST-BUT regarding
morbidity, mortality, virus replication, lesions development in the
lungs and also the neutralizing antibodies levels.
Previous studies had demonstrated that although GP1V and
GP2V were isolated from cows in two neighbor rural properties
during the same bovine vaccinia outbreak, they were genetically
divergent [7,18,20,39] Our study confirmed that the divergence
between GP1V and GP2V also occurs at the biological phenotypic
level. While GP2V did not cause weight loss or death in BALB/c,
GP1V caused weight loss that culminated in the death of infected
mice.
Figure 7. Histological and immunohistochemical analysis of lungs from LST-BUT, ARAV, PSTV and GP2V VACV strains infected
mice. Histological sections of lungs from mice infected with 10
6 PFU of VACV were performed on days 1, 3 and 5 p.i. and positive anti-H3L expression
was evident in inflammatory cell cytoplasms (inserts, arrow-heads) on day 3 p.i in mice infected with LST-BUT, ARAV, PSTV and GP2V. Focal interstitial
pneumonitis ranging from moderate to mild was observed in mice infected with all viruses. Alveolar enlargement (white arrows) due to diffuse
alveolar wall rupture and focal interalveolar septa thickening (long arrows), were observed in lungs of mice infected with LST-BUT, ARAV, PSTV and
GP2V. Vascular congestion, and focal hemorrhage (*) were frequently detected. No lesions or immunostaining were detected in non-infected mice
lungs (see Control in Figure 6). Original magnifications: 635 and 6350 (inserts).
doi:10.1371/journal.pone.0003043.g007
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were all isolated from cows during bovine vaccinia outbreaks,
strains belonging to the other group SAV, BAV and VBH were
isolated from rodents while GP1V was isolated from a cow. Thus,
analyzing these results, there is no obligatory correlation between
the host species where the virus was isolated and the biological
characteristics of VACV strains studied here, which is in
agreement with previous phylogenetic studies [36,39].
VACV has already been isolated from rodents in nature, as
exemplified by BAV, and those animals could be important to the
maintenance and transmission of VACV in nature, as observed for
other Orthopoxvirus [40–42]. Other studies of our group suggest that
excretes from infected mice could be a source of virus elimination
and transmission (unpublished data). This work demonstrated that
BR-VACV strains can cause different types of infections in mice:
clinical (SAV, BAV, GP1V and VBH) and sub-clinical (PSTV,
ARAV and GP2V). Rodents with clinical and sub-clinical disease
could play an important role in VACV maintenance and
transmission to different hosts in nature, what should be further
investigated.
Our results confirmed that there are different populations of
Brazilian VACV strains regarding their virulence, circulating in
nature even during the same bovine vaccinia outbreak, such as
GP1V and GP2V. Regardless the fact that ARAV, GP2V and
PSTV exhibit a low virulence pattern causing sub-clinical disease
in BALB/c mice, they were associated with bovine vaccinia
outbreaks in which in cows, calves and humans were infected,
leading to economic and health problems. Moreover, the co-
circulation of VACV strains with different biological characteris-
tics, could favor events such as recombination that could give
origin to more virulent strains. In conclusion, this work brings new
and relevant data about the biology of VACV strains and reinforce
the need of more studies to elucidate the genotypic and phenotypic
characteristics of those Brazilian VACV strains and not only in
BALB/c model, but also in other rodents and bovines.
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